Although a prior study suggested that indirect inhibition of MYC degradation by targeting glycogen synthase kinase 3β (GSK-3β) can increase doxorubicin sensitivity [46], others have shown that translation inhibition in chemoresistant lymphomas restores sensitivity to doxorubicin. Here, GSK3B is linked to lymphoma.